Guardant Health (GH) Co-ceo Amirali Talasaz Buys $467K of Stock
Co-Chief Executive Officer Amirali Talasaz picked up 111,804 shares of Guardant Health, Inc. stock on June 26, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Amirali Talasaz, Co-Chief Executive Officer at Guardant Health, Inc. ($GH), bought 111,804 shares at an average price of $4.18, worth about $467,340.72, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GH is up 13.1% after 1 week, down 2.5% after 1 month and up 6.3% to date (from the $149.22 close on Jun 26, 2026).
GH
Guardant Health, Inc.
Key Points
- Guardant Health, Inc. Co-CEO Amirali Talasaz bought 111,804 shares on June 26, 2026, for a total value of $467,340.72.
- The stock traded around $150.03 recently, sitting between its 52-week low of $55.38 and high of $183.51.
- Wall Street maintains a strong buy consensus on the stock, with recent target updates from firms like Morgan Stanley and Barclays.
Get $GH trade alerts by text
We text you when insiders, Congress or big funds trade $GH. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Guardant Health, Inc. alert may contain errors. Disclosures
Guardant Health Co-CEO Buys 111,804 Shares
Guardant Health, Inc. (NasdaqGS: GH) Co-Chief Executive Officer Amirali Talasaz bought 111,804 shares of the company on June 26, 2026. The transaction had a total value of $467,340.72, executed at a price of $4.18 per share. This filing gives a look into leadership activity inside the precision oncology firm.
Insider Buying and Selling at Guardant Health, Inc.
The purchase by Talasaz follows other recent insider moves at Guardant Health, Inc. Director Azar Alex M II sold 69 shares on October 14, 2026, at an average price of $159.89 for a total value of $11,032.41 under a planned trade. Insider transactions like these happen for various personal or strategic reasons and do not necessarily signal a broader trend for the company's shares.
Guardant Health Stock Trading Levels
Guardant Health, Inc. shares recently changed hands at $150.03, staying well above the 52-week low of $55.38 while trading below the 52-week high of $183.51. The stock has a 50-day moving average of $161.34 and a 200-day moving average of $120.63. The company carries a market capitalisation of roughly $23.33 billion.
Analysts Set New Price Targets
Wall Street firms maintain an active view on Guardant Health, Inc. with a general recommendation key of strong buy based on 26 analyst opinions. Morgan Stanley maintains an Overweight rating with a $200 price target raised from $185 on October 13, 2026. Barclays also maintains an Overweight rating, lifting its target to $220 from $200 on October 7, 2026. Guggenheim keeps a Buy rating with a $200 target as of October 1, 2026, while UBS maintains a Buy rating with a $225 target set on September 9, 2026.
Inside the Business Operations
Guardant Health, Inc. operates as a precision oncology company providing blood and tissue tests, alongside data sets, in the United States and internationally. Key offerings include the Guardant360 liquid biopsy test and the Shield blood test for colorectal cancer screening. The company is headquartered in Palo Alto, California, and employs 2,490 people.
What to Watch at Guardant Health, Inc.
Investors are looking toward the company's next scheduled financial update on October 28, 2026, for more details on revenue growth and product adoption. Insider filings remain a matter of public record, offering insight into how executives manage their personal holdings over time without serving as investment advice.
Related Filing Alerts
Source: Amirali Talasaz's Form 4 filing on $GH (Jun 26, 2026). Find the original filing: GH Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts